NCI Announces $200M Cancer Vaccine Funding at AACR as mRNA Pipeline Shows Resilience

At the AACR Annual Meeting, the National Cancer Institute (NCI) announced a $200 million funding commitment specifically for cancer vaccine research, partially reversing damaging cuts to the US mRNA research pipeline. The announcement followed a difficult 2025 for federally funded mRNA programs: a proposed 40% NCI budget cut, cancellation of a $590 million Moderna pandemic flu preparedness contract with BARDA, and termination of 22 BARDA mRNA research contracts had created deep uncertainty. The new $200M commitment covers personalized neoantigen vaccines, shared tumor antigen approaches, and combination immunotherapy strategies across cancers including melanoma, lung, pancreatic, and colorectal. Cancer researchers at AACR expressed cautious optimism, noting that many 2025 cuts are being partially reversed. Scientific American simultaneously published a feature warning that ongoing federal funding uncertainty continues to threaten the broader personalized mRNA cancer vaccine pipeline if cuts are not fully restored.